Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Other Accumulated Expenses (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 7 years of Other Accumulated Expenses readings, the most recent being $20.7 million for Q1 2026.

  • On a quarterly basis, Other Accumulated Expenses rose 4757.04% to $20.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $20.7 million, a 4757.04% increase, with the full-year FY2025 number at $598000.0, down 96.49% from a year prior.
  • Other Accumulated Expenses hit $20.7 million in Q1 2026 for Kiniksa Pharmaceuticals International, up from $598000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $22.2 million in Q1 2022 to a low of $111000.0 in Q2 2024.
  • Median Other Accumulated Expenses over the past 5 years was $2.9 million (2023), compared with a mean of $6.1 million.
  • Biggest five-year swings in Other Accumulated Expenses: skyrocketed 7532.99% in 2022 and later plummeted 96.49% in 2025.
  • Kiniksa Pharmaceuticals International's Other Accumulated Expenses stood at $5.8 million in 2022, then surged by 42.39% to $8.2 million in 2023, then surged by 108.06% to $17.0 million in 2024, then plummeted by 96.49% to $598000.0 in 2025, then skyrocketed by 3360.03% to $20.7 million in 2026.
  • The last three reported values for Other Accumulated Expenses were $20.7 million (Q1 2026), $598000.0 (Q4 2025), and $9.0 million (Q3 2025) per Business Quant data.